Bioton amends China contract

Until now, the joint-venture involved the construction of a plant which will produce insulin for the Chinese market from 2009. Following the launch of production, SciGen would supervise the manufacturing process, but exclusive distribution and marketing rights would be entrusted to its Chinese partners. Now, however, the distribution rights will also be held jointly.